Adenosinum Triphosphas (ATP) veterinary grade for parenteral products is handled as a moisture-sensitive, heat-labile active substance. Sterile injectable presentations are manufactured from lyophilised powder rather than terminally sterilised ready-to-use solutions. ATP dissolved in Water for Injections at 2–8 °C undergoes pH-dependent hydrolysis primarily to ADP and AMP. The degradation rate accelerates above pH 7.0 and below pH 4.0. For large-animal metabolic support formulations the bulk solution is adjusted to pH 6.0–6.5 with 0.1 M sodium hydroxide before membrane filtration. A 0.22 µm PVDF filter cartridge is used under aseptic conditions in an ISO 14644-1 Class 5 filling zone. Mannitol is added at 4.0–5.0% w/v as lyoprotectant because ATP alone forms collapse-prone cakes during freeze drying. Fill volume is commonly 5 mL to 20 mL into Type I glass vials. The lyophilisation cycle requires shelf cooling to −40 °C before primary drying at 50–80 µbar chamber pressure. Secondary drying is completed at 25 °C until residual moisture is ≤2.0%. Terminal steam sterilisation is not applied because ATP loses assay potency at 121 °C even for a 15-minute cycle. Bacterial endotoxin limits follow Ph. Eur. 2.6.14. For parenteral veterinary APIs a specification of <0.25 EU/mg is commonly applied. Sterility is tested per Ph. Eur. 2.6.1. Reconstituted solution is held at 2–8 °C and used within 6 h when stability data are not available beyond that point. Calcium- and magnesium-containing diluents are not recommended for reconstitution because ATP chelates divalent cations and may form insoluble complexes. The same incompatibility applies to lactated Ringer's solution in production technical bulletins. Parenteral grade ATP is therefore diluted in 0.9% sodium chloride injection if further dilution is required. Production-scale batches show greatest yield loss during filtration if the solution temperature rises above 10 °C. Jacketed stainless steel tanks and pre-chilled product-contact lines reduce this loss. This is the highest-risk dosage form due to cold-chain dependence and aseptic processing constraints.

What Limits Direct Compression of ATP Tablets in Canine and Feline Dosage Forms?

Direct compression of ATP tablets is constrained by the substance's hygroscopicity and poor compactability. Tablet formulations for companion animals are normally designed at an ATP load of 10–25% w/w. A typical 10 mg feline tablet with total mass 80–100 mg uses mannitol as the primary diluent because lactose is avoided in cats due to lactase insufficiency. Microcrystalline cellulose at 20–30% w/w improves compressibility, but its equilibrium moisture above RH 40% promotes ATP hydrolysis during storage. Crospovidone at 2.0–5.0% w/w is used as disintegrant. Colloidal silicon dioxide at 0.5–1.0% w/w improves flow. Magnesium stearate is kept at 0.5% w/w because higher levels reduce tensile strength. Compression is performed on a rotary tablet press with B-tooling at 8–12 kN compression force. Target hardness is 40–70 N depending on tablet diameter. Feed-frame humidity must be maintained below 30% RH and the powder blend is pre-conditioned in a fluid bed dryer at 25 °C until loss on drying is ≤2.0%. The acid-labile nature of ATP means oral tablets without enteric protection may lose potency in gastric fluid at pH 1.2. A methacrylic acid-ethyl acrylate copolymer enteric coating is applied to a weight gain of 5.0–8.0% in a pan coater with inlet air at 28–32 °C and product temperature at 22–25 °C. Coated tablets are tested for disintegration per Ph. Eur. 2.9.1 using 0.1 M hydrochloric acid for 120 min followed by pH 6.8 phosphate buffer. Dissolution testing per Ph. Eur. 2.9.3 is specified at 45 min in pH 6.8 buffer. Content uniformity follows USP <905> or Ph. Eur. 2.9.40. Punch sticking remains a batch failure mode when API moisture exceeds 2.5% or when punch embossing depth is above 0.15 mm. Anti-hygroscopic packaging is required. Aluminium/PVC cold-form blister with desiccant pouch is used for stability batches stored at 25 °C/60% RH and 40 °C/75% RH.

For capsule manufacturing of feline and canine ATP products, low-shear blending and semi-automatic filling are used because the API is sensitive to high-shear heat. ATP at 20–30% w/w is pre-blended with mannitol or pregelatinised starch in a V-blender at 12–15 rpm for 20 minutes. The blend is passed through a 0.5 mm screen before filling into hypromellose capsules. For feline dose adjustment, geometric dilution with mannitol is used instead of lactose. Filling of 25 mg ATP into size 3 hypromellose capsules at 120 mg total fill weight is a representative production configuration. Powder feed is held at <30% RH using a dehumidified cleanroom. Capsule shells are pre-conditioned at 15–20% moisture to avoid brittleness. Final capsules are polished and packed into HDPE bottles with silica gel desiccant and induction-sealed closures. Dissolution from hypromellose capsules is typically faster than from tablets, but ATP release in stomach pH remains a stability risk. Enteric-coated capsule shells or enteric-coated pellets are required when gastric degradation is not acceptable. For hospital compounding, ATP capsules prepared from API are assigned a beyond-use date not exceeding 30 days at 2–8 °C unless a stability study supports longer storage. No capsule-specific pharmacopoeial monograph exists for veterinary ATP. The relevant test methods are Ph. Eur. 2.9.1 for disintegration, Ph. Eur. 2.9.40 for uniformity of dosage units, and Ph. Eur. 2.2.29 HPLC for assay and related substances.

Water-Soluble Powder, Premix Carrier, and Oral Electrolyte Matrix Differences

In poultry and swine drinking-water applications, powders and feed premixes differ in carrier selection because water-soluble powders must dissolve completely, while veterinary premixes may remain dispersed in a feed matrix. For drinking-water application, ATP is blended with dextrose monohydrate at a ratio of 1.0:9.0 to 1.0:19.0 depending on the intended dose per 100 L of drinking water. Sodium citrate-citric acid buffer is included at 3.0–5.0% w/w to maintain reconstituted pH near pH 6.0. Hard water with total hardness above 250 mg/L CaCO₃ produces turbidity and reduces ATP recovery due to calcium- and magnesium-ATP complexes. Demineralised or softened water is therefore specified in reconstitution instructions. Blending is performed in a 500 L ribbon blender at 10–12 rpm for 20–25 minutes after ATP and carriers are pre-sieved through a 0.5 mm mesh. Blend uniformity is monitored by sampling 10 points and requires relative standard deviation ≤5.0% for ATP content. Fill into foil-lined multi-layer sachets under nitrogen flush prevents moisture uptake. Premix grades for feed mills are manufactured on a silica or wheat bran carrier at ATP concentrations of 2.0–10.0 kg per 100 kg premix. These premixes are not water-soluble and are intended for dry mixing into complete feed at 1.0–2.0 kg premix per tonne. Premix operations reference current GMP for medicated feedingstuffs. Residual solvents are controlled per VICH GL18. Heavy metals are controlled per Ph. Eur. 2.4.8. Poultry drinking-water powder shows a key production failure when bulk product temperature exceeds 25 °C during milling. ATP assay decreases and ADP/AMP related substances increase. The process therefore uses pin milling with chilled nitrogen or cold air at 10–15 °C.

When raw API powder cannot achieve sufficient homogeneity at low inclusion rates, granulated ATP is produced by non-aqueous wet granulation. A high-shear granulator with 5 L bowl is charged with ATP, mannitol, and a 5% w/w ethanolic polyvinylpyrrolidone binder solution. Ethanol is used because aqueous granulation increases local moisture above 10% and accelerates ATP hydrolysis. Impeller speed is set at 300 rpm and chopper at 1500 rpm for 3–5 minutes. The wet mass is extruded through a 0.8 mm screen and dried in a fluid bed dryer at inlet air 25–30 °C. Drying is stopped when loss on drying reaches ≤2.0%. Granule fractions between 0.8 mm and 1.2 mm are selected for feed mixing. Fine particles below 0.8 mm create segregation in hammer-milled feed and are not used for high-inclusion premises unless a dust-suppression oil coating is applied. Feed mill trials show that ATP granules at 2.0 kg per tonne of complete feed achieve better homogeneity than raw API powder when assessed by 10-point sampling. The granule form is preferred for pelleted feed because hard granule surfaces reduce ATP dust contamination in the production line. A critical throughput limit occurs in fluid bed drying when inlet air dew point exceeds 6 °C. Granules become sticky and form agglomerates above this moisture. Cleaned granules are packed in 25 kg multi-wall paper bags with inner polyethylene liner. Assay and related substances are tested by Ph. Eur. 2.2.29 HPLC. No official veterinary granule monograph applies. The manufacturer applies an in-house specification aligned with VICH GL11 for impurities.

When ATP Is Compounded into Ready-to-Use Large-Animal Infusion Solutions

In large-animal critical care, ready-to-use ATP infusion solutions are compounded as extemporaneous sterile products from lyophilised powder or sterile ATP concentrate. The vehicle is 0.9% sodium chloride injection or 5% glucose injection. Lactated Ringer's solution is not used because calcium and magnesium in the vehicle form complexes with ATP. The final ATP concentration is held at 0.5–1.0 mg/mL for continuous infusion. pH is adjusted to pH 6.0–6.5 if the API is dissolved directly. The solution is passed through a 0.22 µm inline filter during administration. In-use stability is limited to 6 h at 2–8 °C; beyond that point hydrolytic degradation to ADP and AMP increases and the solution must be discarded. Heat sterilisation is not used. The compounded product is not intended for multi-dose storage. Endotoxin and sterility assurance depend on the source material meeting Ph. Eur. 2.6.1 and Ph. Eur. 2.6.14. Particulate matter limits follow Ph. Eur. 2.9.19. Publications on ATP adsorption to PVC infusion bags are limited; production pharmacies therefore use polypropylene or polyolefin bags when stability data are absent. This dosage configuration is used in equine and bovine referral hospitals but remains a compounded product rather than a licensed ready-to-use presentation. No terminal sterilisation step is validated for this formulation.

In neonatal calf, foal, and piglet management, oral drench solutions are manufactured as non-sterile aqueous concentrates because ATP is needed in liquid delivery for weak animals. The API is dissolved in purified water containing 0.1% w/w sodium metabisulfite as antioxidant and sodium citrate buffer to hold pH at pH 6.0–6.5. A typical concentrate contains ATP at 5.0–10.0 mg/mL in amber PET bottles. Sodium metabisulfite is preferred over ascorbic acid because ascorbic acid lowers pH below pH 5.0 and accelerates ATP dephosphorylation. Nitrogen sparging before filling and brown glass or opaque PET packaging protect the solution from light. Storage is specified at 2–8 °C for a shelf life of 12 months. At ambient temperature, hydrolytic degradation to ADP and AMP increases. A 30-day in-use study at 25 °C is required if a once-opened bottle is to be used in the field. Additives including calcium gluconate, magnesium sulfate, or phosphate salts are not added because they form complexes or alter ionic strength. Sweeteners such as sodium saccharin at 0.05% w/w may be included for piglet acceptance. The solution is dosed by drench gun or mixed into milk replacer at a final concentration not exceeding 1.0 mg/mL because higher concentrations cause precipitation in milk proteins. Quality control includes pH, clarity, microbial limits per Ph. Eur. 5.1.4, and assay by Ph. Eur. 2.2.29 HPLC.